Our BsADC molecules have strong binding activities to tumor cells with high EpCAM and CLDN3 expression, and also exhibited stronger ADCC, ADCP, and CDC effects than their parental bivalent antibodies on OVCAR-3 cells (Fig. 5A). This evidence concerns the gene EPCAM and neoplasm.